ReviewFrontiers in immunology2019
Pentraxin 3 in Cardiovascular Disease.
Review in Frontiers in immunology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 102 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
102 citing papers in PubMed, 4 syntheses or guidelines pooled it, 164 citations in OpenAlex.
- The Association Between Serum Pentraxin-3 Level at Admission and the Functional Outcome of Patients After Acute Ischemic Stroke: A Meta-Analysis.Balkan medical journal · 2025Pooled it
- Organokines in COVID-19: A Systematic Review.Cells · 2023Pooled it
- The Role of Chronic Inflammation in Polycystic Ovarian Syndrome-A Systematic Review and Meta-Analysis.International journal of molecular sciences · 2021Pooled it
- Higher Plasma Pentraxin-3 Level Predicts Adverse Clinical Outcomes in Patients With Coronary Artery Disease: A Meta-Analysis of Cohort Studies.Frontiers in cardiovascular medicine · 2021Pooled it
- Trial
- Fibro-inflammatory recovery and type 2 diabetes remission following a low calorie diet but not exercise training: A secondary analysis of the DIASTOLIC randomised controlled trial.Diabetic medicine : a journal of the British Diabetic Association · 2022Trial
- Cardiac Rehabilitation with Targeted Intensity Improves Cardiopulmonary Functions Accompanying with Reduced Copeptin Level in Patients with Coronary Artery Disease.Journal of cardiovascular translational research · 2021Trial
- Pentraxin 3 and the TyG Index as Two Novel Markers to Diagnose NAFLD in Children.Disease markers · 2021Trial
- Circulating biomarkers and cardiac function over 3 years after chemotherapy with anthracyclines: the ICOS-ONE trial.ESC heart failure · 2020Trial
- Proteomic Profiling of Endothelial Cells Under Laminar Shear Stress Confirms the Importance of KLF4 in the Regulation of Membrane Protein Expression Compared to Oscillatory Flow.Journal of proteome research · 2026Article
- Effects of Environmental Temperature During Cultivation of Broccoli Microgreens on Hematological Parameters, Molecular Markers, and Myocardial Antioxidant Status in Swiss Mice.Food science & nutrition · 2026Article
- Targeting of Pentraxin 3 Alleviated Cardiac Hypertrophy in Mice Induced by Angiotensin II.Clinical and experimental pharmacology & physiology · 2026Article
- Investigation of the relationship between pentraxin 3 levels and pain in patients with primary dysmenorrhea.BMC women's health · 2026Article
- Beyond clinical criteria: emerging biomarkers and advanced imaging in the diagnosis, monitoring and treatment of vasculitides.Frontiers in medicine · 2026Review
- A machine learning model including pentraxin-3 as predictor of outcomes in community-acquired pneumonia.Journal of translational medicine · 2025Observational
- Clinical application of butylphthalide sequential therapy on PTX-3, S100B, IL-6 in acute cerebral infarction.Journal of medical biochemistry · 2025Article
- Estimating the Contribution of Renal Function to Endothelial Dysfunction and Subclinical Inflammation with a Two-Cohort Study: Living Kidney Donors and Their Transplant Recipients.International journal of molecular sciences · 2025Observational
- Reperfusion injury in STEMI: a double-edged sword.The Egyptian heart journal : (EHJ) : official bulletin of the Egyptian Society of Cardiology · 2025Review
- Potential role of pentraxin 3 (PTX3) and aldehyde dehydrogenase (ALDH) in liver cirrhotic patients: predicting and diagnostic impact in hepatocellular carcinoma (HCC) development.Molecular biology reports · 2025Article
- Molecular Diagnostics in Heart Failure: From Biomarkers to Personalized Medicine.Diagnostics (Basel, Switzerland) · 2025Review
42 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The long pentraxin PTX3 is a member of the pentraxin family produced locally by stromal and myeloid cells in response to proinflammatory signals and microbial moieties. The prototype of the pentraxin family is C reactive protein (CRP), a widely-used biomarker in human pathologies with an inflammatory or infectious origin. Data so far describe PTX3 as a multifunctional protein acting as a functional ancestor of antibodies and playing a regulatory role in inflammation. Cardiovascular disease (CVD) is a leading cause of mortality worldwide, and inflammation is crucial in promoting it. Data from animal models indicate that PTX3 can have cardioprotective and atheroprotective roles regulating inflammation. PTX3 has been investigated in several clinical settings as possible biomarker of CVD. Data collected so far indicate that PTX3 plasma levels rise rapidly in acute myocardial infarction, heart failure and cardiac arrest, reflecting the extent of tissue damage and predicting the risk of mortality.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.